Want to see ANL full AI Analyst Report?
Top Page
Adlai Nortye Ltd. Sponsored ADR
(NASDAQ:ANL)
Select Model
Select Model
Rating:50Neutral
Price Target:
$13.50
▲(8.00% Upside)
Action:N/A
Date:08/17/26
The score is held back primarily by weak fundamentals—heavy losses, persistent cash burn, and negative equity implying elevated financing risk. Technical indicators are moderately positive (price above major moving averages with a positive MACD), which partially offsets the fundamental weakness, while valuation remains challenged due to the company being unprofitable and lacking dividend support.
Positive Factors
Strengthened Funding Base
The enlarged cash position provides resources to fund multiple clinical programs and operations through upcoming milestones. It improves near-term execution capacity, although future dilution remains a consideration for shareholders.
Negative Factors
Deep Losses and Unsustainable Margins
The current revenue base is far too small to absorb research, development and operating costs, leaving profitability highly dependent on future clinical success. Sustained negative margins could require additional capital before products generate recurring sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened Funding Base
The enlarged cash position provides resources to fund multiple clinical programs and operations through upcoming milestones. It improves near-term execution capacity, although future dilution remains a consideration for shareholders.
Read all positive factors
Adlai Nortye Ltd. Sponsored ADR (ANL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$882.25M
Dividend YieldN/A
Average Volume (3M)206.94K
Price to Earnings (P/E)―
Beta (1Y)2.21
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees109
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding72,859,474
10 Day Avg. Volume265,932
30 Day Avg. Volume206,938
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.82
Price to Sales (P/S)3.03
P/FCF Ratio-0.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.67Price Target Upside97.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Adlai Nortye Ltd. Sponsored ADR Business Overview & Revenue Model
Company Description
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Pha...
How the Company Makes Money
null...
Adlai Nortye Ltd. Sponsored ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
17
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.68M | 5.00M | 0.00 | 0.00 | 0.00 | 45.73M |
| Gross Profit | 19.68M | 5.00M | 0.00 | 0.00 | 0.00 | 45.73M |
| EBITDA | -21.47M | -32.63M | -48.05M | -106.22M | -56.32M | -53.51M |
| Net Income | -22.53M | -35.53M | -51.87M | -109.23M | -58.79M | -56.68M |
Balance Sheet | ||||||
| Total Assets | 248.36M | 34.43M | 71.27M | 130.19M | 72.59M | 131.69M |
| Cash, Cash Equivalents and Short-Term Investments | 232.82M | 23.79M | 60.91M | 98.50M | 64.05M | 117.94M |
| Total Debt | 26.70M | 26.38M | 27.23M | 31.55M | 6.54M | 13.35M |
| Total Liabilities | 33.53M | 42.76M | 45.78M | 55.14M | 313.89M | 317.11M |
| Stockholders Equity | 214.83M | -8.32M | 25.48M | 75.05M | -241.29M | -185.43M |
Cash Flow | ||||||
| Free Cash Flow | -58.25M | -33.73M | -51.99M | -56.85M | -44.49M | -4.15M |
| Operating Cash Flow | -57.97M | -33.54M | -51.82M | -56.65M | -43.22M | -3.03M |
| Investing Cash Flow | -98.02M | -15.62M | 28.07M | -10.95M | 28.38M | -54.86M |
| Financing Cash Flow | 209.13M | -3.82M | -6.58M | 116.24M | -6.78M | 97.20M |
Adlai Nortye Ltd. Sponsored ADR Risk Analysis
Adlai Nortye Ltd. Sponsored ADR disclosed 134 risk factors in its most recent earnings report. Adlai Nortye Ltd. Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adlai Nortye Ltd. Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $882.25M | -7.01 | -21.82% | ― | ― | ― | |
49 Neutral | $94.71M | -1.18 | -70.14% | ― | ― | 16.04% | |
47 Neutral | $45.01M | -4.39 | -45.89% | ― | -100.00% | 68.62% | |
43 Neutral | $31.09M | -0.65 | -93.08% | ― | 110.08% | 76.04% | |
40 Underperform | $41.65M | -0.91 | -160.72% | ― | 893.01% | 41.74% |
* Healthcare Sector Average
ANL
Adlai Nortye Ltd. Sponsored ADR
13.70
12.06
735.37%
VERU
Veru
2.64
-0.85
-24.36%
ALGS
Aligos Therapeutics
6.67
-3.54
-34.67%
GNTA
Genenta Science SpA Sponsored ADR
1.26
-2.23
-63.90%
ACRV
Acrivon Therapeutics, Inc.
2.21
0.88
66.17%
RADX
Radiopharm Theranostics Limited Sponsored ADR
2.44
-3.16
-56.43%
Adlai Nortye Ltd. Sponsored ADR Corporate Events
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026
Aug 14, 2026
Adlai Nortye Ltd., a clinical-stage biotechnology company focused on innovative oncology drugs such as pan-RAS(ON) inhibitors and immune-modulating antibodies, is expanding its clinical and operational footprint in the U.S. and Singapore to suppor...
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial
Aug 3, 2026
On August 3, 2026, Adlai Nortye announced that it has submitted a Clinical Trial Notification to Australia’s Therapeutic Goods Administration and secured Human Research Ethics Committee approval to start a phase I trial of AN4035, a CEACAM5-...
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025
Jul 17, 2026
On July 16, 2026, Adlai Nortye reported that the first patient in the United States has been dosed in the intermittent weekly (QW) arm of its global Phase 1 trial of AN9025, an oral pan-RAS(ON) inhibitor for advanced solid tumors harboring RAS mut...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.